← Leaderboards
Roberto F. Machado
Indiana University Indianapolis
$15,563,589
Attributed
$20,331,102
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,331,102 · 7
By mechanism
R01$17,097,914 · 4
T32$1,528,633 · 1
T35$1,047,645 · 1
K23$656,910 · 1
Top collaborators
- Viswanathan Natarajan8 shared
- Robert S. Tepper5 shared
- Brittney-Shea Herbert4 shared
- You-Yang Zhao4 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Brittney-Shea Herbert$3,658,235
- Joel James$453,806
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsMolecularFunctional DisorderCessation Of LifeLungPrematureResponseEndothelial CellsMortalityHypoxiaPathway InteractionsGeneticPulmonary Arterial HypertensionVascular RemodelingScientistCareerPhysiciansPathogenesisPredispositionAnimal ModelTherapeutic TargetCellsPulmonary Artery StructureSignal Transduction
Grant awards (43)
Vascular Targeting Genomic & Genetic Strategies for Acute Chest Syndrome$709,465
R01 · FY2025 · HL · contact PI
NAD-dependent Signaling and Pulmonary Vascular Remodeling in PAH$707,644
R01 · FY2025 · HL · contact PI
Vascular Targeting Genomic & Genetic Strategies for Acute Chest Syndrome$695,276
R01 · FY2024 · HL · contact PI
NAD-dependent Signaling and Pulmonary Vascular Remodeling in PAH$693,491
R01 · FY2024 · HL · contact PI
IU Training Program in Molecular Physiology and Clinical Mechanisms of Lung Disease$427,952
T32 · FY2024 · HL · contact PI
Short-Term Training Program In Biomedical Sciences$284,895
T35 · FY2024 · HL · contact PI
NAD-dependent Signaling and Pulmonary Vascular Remodeling in PAH$65,266
R01 · FY2024 · HL · contact PI
Vascular Targeting Genomic & Genetic Strategies for Acute Chest Syndrome$753,340
R01 · FY2023 · HL · contact PI
NAD-dependent Signaling and Pulmonary Vascular Remodeling in PAH$710,428
R01 · FY2023 · HL · contact PI
Role of Sphingolipid pathways in the pathobiology of PAH$687,959
R01 · FY2023 · HL · contact PI
IU Training Program in Molecular Physiology and Clinical Mechanisms of Lung Disease$306,366
T32 · FY2023 · HL · contact PI
Short-Term Training Program In Biomedical Sciences$273,836
T35 · FY2023 · HL · contact PI
NAD-dependent Signaling and Pulmonary Vascular Remodeling in PAH$719,485
R01 · FY2022 · HL · contact PI
Role of Sphingolipid pathways in the pathobiology of PAH$687,959
R01 · FY2022 · HL · contact PI
Short-Term Training Program In Biomedical Sciences$265,697
T35 · FY2022 · HL · contact PI
IU Training Program in Molecular Physiology and Clinical Mechanisms of Lung Disease$226,328
T32 · FY2022 · HL · contact PI
Role of Sphingolipid pathways in the pathobiology of PAH$687,959
R01 · FY2021 · HL · contact PI
Vascular-targeting genomic and genetic strategies for acute chest syndrome$588,405
R01 · FY2021 · HL · contact PI
Short-Term Training Program In Biomedical Sciences$223,217
T35 · FY2021 · HL · contact PI
IU Training Program in Molecular Physiology and Clinical Mechanisms of Lung Disease$189,990
T32 · FY2021 · HL · contact PI
Role of Sphingolipid pathways in the pathobiology of PAH$702,584
R01 · FY2020 · HL · contact PI
Vascular-targeting genomic and genetic strategies for acute chest syndrome$588,405
R01 · FY2020 · HL · contact PI
IU Training Program in Molecular Physiology and Clinical Mechanisms of Lung Disease$377,997
T32 · FY2020 · HL · contact PI
Vascular-targeting genomic and genetic strategies for acute chest syndrome$595,016
R01 · FY2019 · HL · contact PI
Novel mechanisms of obliterative pulmonary vascular remodeling and sever pulmonary arterial hypertension$520,864
R01 · FY2019 · HL
Role of Sphingolipid Pathways in the Pathobiology of PAH$412,034
R01 · FY2019 · HL · contact PI
Vascular-targeting genomic and genetic strategies for acute chest syndrome$624,920
R01 · FY2018 · HL · contact PI
Novel mechanisms of obliterative pulmonary vascular remodeling and sever pulmonary arterial hypertension$534,114
R01 · FY2018 · HL
Role of Sphingolipid Pathways in the Pathobiology of PAH$426,409
R01 · FY2018 · HL · contact PI
Novel mechanisms of obliterative pulmonary vascular remodeling and severe pulmonary arterial hypertension$679,575
R01 · FY2017 · HL
Vascular-targeted genomic and genetic strategies for acute chest syndrome$513,649
R01 · FY2017 · HL · contact PI
Role of Sphingolipid Pathways in the Pathobiology of PAH$469,981
R01 · FY2017 · HL · contact PI
Novel mechanisms of obliterative pulmonary vascular remodeling and severe pulmonary arterial hypertension$679,575
R01 · FY2016 · HL
Vascular-targeted genomic and genetic strategies for acute chest syndrome$513,649
R01 · FY2016 · HL · contact PI
Role of Sphingolipid Pathways in the Pathobiology of PAH$469,736
R01 · FY2016 · HL · contact PI
Vascular-targeted genomic and genetic strategies for acute chest syndrome$521,655
R01 · FY2015 · HL · contact PI
Vascular-targeted genomic and genetic strategies for acute chest syndrome$519,007
R01 · FY2014 · HL · contact PI
Carbon monoxide therapy for severe pulmonary arterial hypertension$131,382
K23 · FY2014 · HL · contact PI
Vascular-targeted genomic and genetic strategies for acute chest syndrome$620,064
R01 · FY2013 · HL · contact PI
Carbon monoxide therapy for severe pulmonary arterial hypertension$131,382
K23 · FY2013 · HL · contact PI
Carbon monoxide therapy for severe pulmonary arterial hypertension$131,382
K23 · FY2012 · HL · contact PI
Carbon monoxide therapy for severe pulmonary arterial hypertension$131,382
K23 · FY2011 · HL · contact PI
Carbon monoxide therapy for severe pulmonary arterial hypertension$131,382
K23 · FY2010 · HL · contact PI